Table 2 Univariate and multivariate analysis of prognostic factors of cancer-specific survival using Cox regression model.
Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Age at prostate cancer diagnosis, years (≥ 70 vs. < 70) | 0.673 (0.273–1.658) | 0.3896 | ||
PSA at prostate diagnosis, ng/mL (< 100 vs. ≥ 100) | 2.364 (0.695–8.045) | 0.1684 | ||
Clinical stage (T3-4 vs. T1-2) | 0.766 (0.315–1.860) | 0.5556 | ||
TTCRPC, month (≥ 8 vs. < 8) | 1.266 (0.509–3.148) | 0.6118 | ||
TTCRPC, month (≥ 9 vs. < 9) | 1.532 (0.648–3.621) | 0.3312 | ||
Local therapy (yes or no) | 1.467 (0.604–3.566) | 0.5381 | ||
(Radical prostatectomy vs. radiation) | 2.144 (0.679–6.767) | 0.1936 | ||
Nadir PSA, ng/ml (≥ 0.2 vs. < 0.2) | 1.236 (0.510–2.995) | 0.6382 | ||
PSA reduction rate, % (< 99.5 vs. ≥ 99.5) | 1.636 (0.631–4.241) | 0.3107 | ||
TnPSA, months (≤ 12 vs. > 12) | 1.768 (0.744–4.204) | 0.1969 | ||
Age at CRPC diagnosis, years (≥ 75 vs. < 75) | 0.689 (0.289–1.644) | 0.4014 | ||
TTCRPC, month (≤ 24 vs. > 24) | 2.292 (0.949–5.538) | 0.0652 | ||
TTCRPC, month (≤ 12 vs. > 12) | 5.692 (1.972–16.42) | 0.0013* | 3.714 (1.233–11.19) | 0.0197* |
PSA at CRPC diagnosis, ng/mL (≥ 10 vs. < 10) | 0.755 (0.101–5.658) | 0.7845 | ||
PSADT, month (≤ 3 vs. > 3) | 3.738 (1.496–9.339) | 0.0048* | 3.005 (1.157–7.809) | 0.0239* |
Treatment groupa | ||||
DOC vs. ARAT | 2.323 (0.800–6.757) | 0.1212 | ||
Other therapiesb alone vs. DOC/ARAT | 0.708 (0.259–1.937) | 0.5017 | ||
